Related Experiment Video

Updated: Mar 29, 2026

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

6.8K

Fibronectin-targeted drug delivery in cancer

Heena Kumra1, Dieter P Reinhardt1

  • 1Faculty of Medicine, Department of Anatomy and Cell Biology, McGill University, Montreal, QC H3A 0C7, Canada; Faculty of Dentistry, McGill University, Montreal, QC H3A 0C7, Canada.

Advanced Drug Delivery Reviews
|December 8, 2015
PubMed

Insights

Fibronectin

Area of Science:

  • Oncology
  • Biochemistry
  • Molecular Biology

Background:

  • Fibronectin is an extracellular matrix protein with critical roles in development and disease.
  • Alternative splicing creates fibronectin isoforms, including oncofetal forms (EDA, EDB) re-expressed in tumors.
  • These oncofetal fibronectin isoforms are key markers of angiogenesis, vital for tumor growth.

Purpose of the Study:

  • To review recent advancements in fibronectin EDA and EDB domain-based therapeutic strategies for cancer treatment.
  • To highlight the use of these domains in targeted drug delivery, imaging, and vaccine development for various cancers.

Main Methods:

  • This review synthesizes findings from preclinical and clinical studies on fibronectin-targeted cancer therapies.
  • Literature search focused on therapeutic applications utilizing fibronectin EDA and EDB domains.

Main Results:

  • Fibronectin EDA and EDB domains are effectively targeted for delivering therapeutic agents (cytokines, drugs, radioisotopes) to tumors.
  • These domains facilitate the development of novel imaging strategies for tumor detection and characterization.
  • Fibronectin EDA and EDB-based vaccines show promise for cancer prevention and treatment.

Conclusions:

  • Fibronectin EDA and EDB domains represent valuable targets for developing innovative cancer therapies.
  • Targeted delivery, imaging, and vaccine strategies based on these domains offer significant therapeutic potential.
  • Further research into fibronectin-based approaches could lead to improved cancer treatment outcomes.
Keywords:
Blood vesselsCancerDrug targetFibronectinImagingTumorVaccination

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
96
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
109
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Fibronectins Connect Cells with ECM01:25

Fibronectins Connect Cells with ECM

Fibronectin is an adhesive glycoprotein present in the extracellular matrix of embryogenic and adult tissue. These molecules primarily aid in regulating cell motility and attachment. A fibronectin molecule is composed of two identical polypeptide chains attached to each other by a pair of disulfide bonds at the C-terminal.
Both proteoglycans and collagen are attached to fibronectin proteins, which, in turn, are attached to integrin proteins. These integrin proteins interact with transmembrane...
3.7K